Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MandA

- PMLiVE

Valeant shares slide on fears of filing default

Cuts revenue forecasts for 2016 following report of fourth-quarter loss

- PMLiVE

FDA allows accelerated review for rivals to over-priced drugs

Aims to combat growing trend in exploitation of sole-source drug pricing

- PMLiVE

As CEO returns, Valeant admits SEC probe

Embattled firm's problems continue

- PMLiVE

Valeant names Schiller interim CEO as Pearson battles illness

Former CFO fills in and Ingram is appointed interim chairman of the board

- PMLiVE

PBMs drop Philidor, and Valeant follows suit

Comes after allegations of impropriety

- PMLiVE

Valeant adds member to board of directors

President of ValueAct Capital G. Mason Morfitadded to team

- PMLiVE

Valeant shares plummet on claims of inflated revenues

California lawsuit raises questions about relationship with Philidor Rx

- PMLiVE

Bio investors react as Clinton tweet pledges pricing crackdown

Pharma companies come under scrutiny for pricing policies

- PMLiVE

Valeant adds Robert Hale to board of directors

And Jeffrey Ubben resigns from the board

- PMLiVE

Valeant swoops on Sprout to claim female sexual disorder drug

Comes in the same week that firm gained US approval for its ‘little pink pill’

- PMLiVE

FDA approves first female sexual disorder drug

The ‘little pink pill’ has had a difficult path to market and comes with safety warnings

- PMLiVE

Valeant buys Amoun Pharma for larger slice of MENA market

Comes after Canadian firm recently bought Salix for $11bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links